Chronic pain care is shifting to indication-specific, non-opioid therapies, creating opportunities for durable treatments, precision tools and integrated care for aging populations.

Dublin, Sept. 17, 2026 (GLOBE NEWSWIRE) -- "Chronic Pain - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering.

Chronic Pain Market to Reach Steady Growth Through 2036, Driven by Targeted Therapies and Rising Patient Burden

The chronic pain market across the seven major markets (7MM) was valued at approximately USD 12 billion in 2025 and is forecast to expand at a CAGR of 5.1% from 2026 to 2036. Growth is expected to be supported by a rising patient population, improved diagnosis, greater disease awareness, persistent unmet medical needs, and the anticipated introduction of advanced, indication-specific therapies.

The "Chronic Pain - Market Insights, Epidemiology and Market Forecast - 2036" report provides a comprehensive assessment of the chronic pain market in the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan. It examines historical and forecast epidemiology, treatment practices, market size, therapy uptake, competitive dynamics, reimbursement, pricing, and commercial opportunities from 2022 to 2036.

Chronic Pain Market Size and Epidemiology Highlights

The 7MM chronic pain market reached approximately USD 12 billion in 2025.
The market is projected to grow at a CAGR of 5.1% between 2026 and 2036.
The United States chronic pain market was valued at approximately USD 8 billion in 2025.
EU4 and the United Kingdom generated approximately USD 3 billion in 2025, with Germany contributing more than USD 900 million.
The United States recorded approximately 62 million prevalent chronic pain cases in 2025, including around 44 million diagnosed prevalent cases.
Across EU4 and the United Kingdom, moderate chronic pain represented approximately 26 million cases in 2025, followed by severe pain at around 14 million and mild pain at approximately 12 million.
Females accounted for approximately 31 million diagnosed prevalent cases in EU4 and the United Kingdom, compared with around 21 million among males.
In Japan, adults aged 65 years and older represented the largest patient segment, accounting for approximately 6 million prevalent cases in 2025.

Chronic back pain remains a major contributor to the overall disease burden, particularly in aging markets such as Japan. In 2025, Japan recorded approximately 10 million chronic back pain cases, followed by osteoarthritis with around 7 million cases and rheumatoid arthritis with approximately 3 million. Fibromyalgia, neuropathic pain, and migraine also represented substantial patient populations. The continued expansion of musculoskeletal pain is expected to reshape the chronic pain treatment market through 2036.

Chronic Pain Treatment and Competitive Landscape

Chronic pain management combines pharmacological treatment, interventional procedures, physical therapy, exercise, psychological support, and multidisciplinary rehabilitation. Treatment selection depends on the underlying indication, pain severity, functional impairment, comorbidities, previous therapy, and individual patient requirements. Despite multiple available options, many patients continue to experience inadequate pain control, recurrent symptoms, functional limitations, and treatment-related tolerability concerns.

The marketed chronic pain treatment landscape includes EXILBY, NUCYNTA ER, BELBUCA, and XTAMPZA ER for chronic back pain; ZILRETTA and JOYCLU for osteoarthritis; EMGALITY, VYEPTI, AIMOVIG, AJOVY, BOTOX, and QULIPTA/AQUIPTA for migraine; TONMYA for fibromyalgia; and TARLIGE, QUTENZA, and HORIZANT for neuropathic pain. Competition is increasingly developing around individual chronic pain indications rather than a single, broadly defined therapeutic market.

Atogepant, marketed by AbbVie as QULIPTA in the United States and AQUIPTA in Europe, is approved for migraine prevention in more than 60 countries. In February 2026, AbbVie received marketing approval in Japan for the prevention of migraine attacks in adults. In April 2026, the company also presented Phase III findings evaluating atogepant in combination with onabotulinumtoxinA.

Chronic Pain Pipeline and Emerging Therapies

The chronic pain pipeline is moderately diversified across chronic lower back pain, osteoarthritis, migraine, fibromyalgia, and neuropathic pain. Leading late-stage assets include abobotulinumtoxinA (DYSPORT), XEOMIN, and rimegepant (NURTEC) for migraine; TLC599, lorecivivint, MOTYS, and orforglipron for osteoarthritis; suzetrigine (JOURNAVX) for painful diabetic peripheral neuropathy; AXS-14 (esreboxetine) for fibromyalgia; and Vicatertide (SB-01), rexlemestrocel-L, SP-102 (SEMDEXA), and VER-01 (EXILBY) for chronic lower back pain.

SL-1002 from Saol Therapeutics is an injectable chemoneurolytic candidate under development for chronic knee pain associated with osteoarthritis. Following completion of Phase II evaluation, the therapy advanced toward Phase III development in April 2025, and a Phase III trial began in November 2025 in patients with mild-to-moderate knee osteoarthritis.

Recent chronic pain drug development updates include positive Phase III BEOND topline results for Ipsen's DYSPORT in migraine prevention, reported in July 2026. In June 2026, Eli Lilly reported additional Phase III TRIUMPH-1 findings for retatrutide, including improvements in knee osteoarthritis pain. Novo Nordisk also initiated the Phase III AMAZE 5 and AMAZE 6 trials in April 2026 to evaluate once-weekly zenagamtide in adults with overweight or obesity and knee osteoarthritis.

Market Opportunities and Unmet Needs

The absence of predictive biomarkers continues to limit precision treatment selection.
Persistent reliance on symptomatic analgesia restricts long-term disease management.
Demand remains high for durable and long-acting therapies that reduce repeat treatment burden.
Fragmented epidemiological evidence complicates market sizing across chronic pain indications.
Delayed diagnosis and fragmented multidisciplinary care can postpone access to advanced therapies.
Trial-and-error use of NSAIDs, opioids, antidepressants, and anticonvulsants may slow the adoption of newer targeted treatments.

Novel non-opioid analgesics, biologics, regenerative therapies, and neuromodulatory approaches are expected to influence the future chronic pain treatment paradigm. These therapies are being developed to improve efficacy, durability, function, and tolerability while addressing limitations associated with conventional analgesic treatment. Following its anticipated US launch, DYSPORT is expected to achieve moderate uptake in migraine prevention, supported by clinician familiarity and its established clinical profile.

Market Access, Pricing, and Strategic Analysis

The report evaluates country-specific reimbursement, pricing, cost-effectiveness, patient support programs, out-of-pocket costs, and access through public and private insurance systems. In the United States, reimbursement depends on payer-specific coverage, coding, and payment criteria. ZILRETTA, for example, offers co-pay support for eligible commercially insured patients, while Medicare Part B generally covers 80% of the Medicare-approved amount when treatment is medically necessary and administered by a healthcare professional.

The analysis also incorporates insights from more than 25 key opinion leaders across major markets, including experts associated with Harvard University, Brigham and Women's Hospital, and Friedrich Schiller University Jena. These perspectives support the assessment of clinical practices, prescribing patterns, patient adherence, therapy switching, market access, pipeline prioritization, and emerging treatment adoption.

Report Coverage

Chronic pain epidemiology and patient population forecasts through 2036
Historical and forecast chronic pain market size across the 7MM
Approved therapy profiles and late-stage pipeline analysis
Drug uptake, peak patient share, and sales forecasts
Competitive landscape, pricing trends, and analogue assessment
Market access and reimbursement analysis
SWOT and therapy attribute analysis
Unmet needs, treatment practices, and market opportunities
Expert perspectives on clinical development and commercial adoption

The report is designed to support pharmaceutical companies, investors, healthcare organizations, and other industry stakeholders in evaluating chronic pain market opportunities, prioritizing pipeline assets, strengthening launch strategies, and understanding the competitive factors expected to shape the 7MM chronic pain therapeutics market through 2036.

Key Topics Covered:

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events
4.1. Key Transactions and Collaborations
4.2. News Flow

5. Epidemiology and Market Forecast Methodology

6. Chronic Pain Market Overview at a Glance
6.1. Market Share (%) Distribution of Chronic Pain by Therapies in the 7MM in 2025

7. Disease Background and Overview
7.1. Introduction
7.2. Types of Chronic Pain
7.3. Classification of Chronic Pain
7.4. Sign and Symptoms of Chronic Pain
7.5. Causes and Risk factors of Chronic Pain
7.5.1. Causes of Chronic Pain
7.6. Pathophysiology of Chronic Pain
7.7. Diagnosis of Chronic Pain
7.7.1. Medical History Review
7.7.2. Physical Examination
7.7.3. Pain Assessment Tools
7.7.4. X-rays
7.7.5. Magnetic Resonance Imaging (MRI)
7.7.6. Computed Tomography (CT) Scans
7.7.7. Electromyography (EMG) and Nerve Conduction Studies
7.7.8. Blood Tests
7.7.9. Bone Scans
7.7.10. Nerve Blocks and Diagnostic Injections
7.7.11. Psychological Evaluation
7.7.12. Ultrasound
7.8. Diagnostic Algorithm
7.9. Differential Diagnosis
7.10. Diagnostics guidelines
7.10.1. The American Headache Society Consensus Statement, 2021
7.10.2. American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity
7.10.3. VA/DoD Clinical Practice Guidelines Use of Opioids in the Assessment of Chronic Pain, 2022
7.10.4. German Society of Neurology Guidelines for Neuropathic Pain, 2021
7.10.5. NICE Guidelines for the Assessment and Diagnosis of Chronic Pain (Primary and Secondary) in Adults, 2021
7.10.6. NICE Guidelines for lower back pain and sciatica, 2020
7.10.7. Japanese Clinical Practice Guidelines for the Management of Chronic Pain, 2021
7.10.8. Japanese Orthopedic Association Clinical Practice Guideline for Low Back Pain (Journal of Orthopaedic Science, 2021)
7.11. Treatment of Chronic Pain
7.12. Treatment Algorithm of Chronic Pain
7.13. Treatment Guidelines
7.13.1. A Clinical Practice Guideline from the American College of Physicians for Low Back Pain, 2017
7.13.2. USA / International reference NeuPSIG (IASP Special Interest Group) for Chronic Neuropathic Pain, 2025
7.13.3. VA/DoD Clinical Practice Guidelines Use of Opioids in the Management of Chronic Pain, 2022
7.13.4. CDC Clinical Practice Guideline recommendations for Prescribing Opioids for Pain, 2022
7.13.5. NICE Guidelines for the Assessment and Treatment of Chronic Pain (Primary and Secondary) in Adults, 2021
7.13.6. EULAR recommendations for the management of rheumatoid arthritis, 2025
7.13.7. American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis, 2021
7.13.8. German Society of Neurology Guidelines for Non-interventional Therapy of Neuropathic Pain, 2021
7.13.9. French Society of Neurology Neuropathic Pain Guideline, 2024
7.13.10. European Headache Federation, 2022
7.13.11. The Italian Society for Rheumatology Clinical Practice Guidelines for Rheumatoid Arthritis, 2019
7.13.12. Japanese Clinical Practice Guidelines for the Management of Chronic Pain, 2021
7.13.13. Japanese Orthopaedic Association Clinical Practice Guideline for Low Back Pain (Journal of Orthopaedic Science, 2021)
7.13.14. Japanese Society of Neurology (Clinical Practice Guideline for Headache Disorders), 2021

8. Epidemiology and Patient Population
8.1. Key Findings
8.2. Assumptions and Rationale: 7MM
8.2.1. United States
8.2.2. EU4 and the UK
8.2.2.1. Germany
8.2.2.2. France
8.2.2.3. Italy
8.2.2.4. Spain
8.2.2.5. United Kingdom
8.2.3. Japan
8.3. Total Diagnosed Prevalent Cases of Chronic Pain in the 7MM
8.4. The US
8.4.1. Total Prevalent Cases of Chronic Pain in the US
8.4.2. Total Diagnosed Prevalent Cases of Chronic Pain in the US
8.4.3. Severity-specific Diagnosed Prevalent Cases of Chronic Pain in the US
8.4.4. Gender-specific Diagnosed Prevalent Cases of Chronic Pain in the US
8.4.5. Age-specific Diagnosed Prevalent Cases of Chronic Pain in the US
8.4.6. Cause-specific Diagnosed Prevalent Cases of Chronic Pain in the US
8.4.7. Total Treated Cases of Chronic Pain in the US
8.5. EU4 and the UK
8.5.1. Total Prevalent Cases of Chronic Pain in EU4 and the UK
8.5.2. Total Diagnosed Prevalent Cases of Chronic Pain in EU4 and the UK
8.5.3. Severity -specific Diagnosed Prevalent Cases of Chronic Pain in EU4 and the UK
8.5.4. Gender-specific Diagnosed Prevalent Cases of Chronic Pain in EU4 and the UK
8.5.5. Age-specific Diagnosed Prevalent Cases of Chronic Pain in EU4 and the UK
8.5.6. Cause-specific Diagnosed Prevalent Cases of Chronic Pain in EU4 and the UK
8.5.7. Total Treated Cases of Chronic Pain in EU4 and the UK
8.6. Japan
8.6.1. Total Prevalent Cases of Chronic Pain in Japan
8.6.2. Total Diagnosed Prevalent Cases of Chronic Pain in Japan
8.6.3. Severity -specific Diagnosed Prevalent Cases of Chronic Pain in Japan
8.6.4. Gender-specific Diagnosed Prevalent Cases of Chronic Pain in Japan
8.6.5. Age-specific Diagnosed Prevalent Cases of Chronic Pain in Japan
8.6.6. Cause-specific Diagnosed Prevalent Cases of Chronic Pain in Japan
8.6.7. Total Treated Cases of Chronic Pain in Japan

9. Patient Journey

10. Marketed Drug
10.1. Marketed Drugs: Competitive Landscape
10.2. Atogepant (AQUIPTA,QULIPTA): AbbVie
10.2.1. Product Description
10.2.2. Regulatory Milestones
10.2.3. Other Developmental Activities
10.2.4. Summary of Pivotal Trials
10.2.5. Clinical Development Activities
10.2.5.1. Clinical Trials Information
10.2.6. Analyst View
10.3. Triamcinolone acetonide extended-release injectable suspension (ZILRETTA): Pacira Pharmaceuticals
10.3.1. Product Description
10.3.2. Regulatory Milestones
10.3.3. Other Developmental Activities
10.3.4. Summary of Pivotal Trials
10.3.5. Clinical Development
10.3.5.1. Clinical Trials Information
10.3.6. Analyst View
10.4. Galcanezumab (EMGALITY): Eli Lilly and Company
10.4.1. Product Description
10.4.2. Regulatory Milestones
10.4.3. Other Developmental Activities
10.4.4. Summary of Pivotal Trials
10.4.5. Analyst View
10.5. Eptinezumab (VYEPTI): Lundbeck Seattle BioPharmaceuticals
10.5.1. Product Description
10.5.2. Regulatory Milestones
10.5.3. Other Developmental Activities
10.5.4. Summary of Pivotal Trials
10.5.5. Clinical Development
10.5.5.1. Clinical Trials Information
10.5.6. Analyst View
10.6. Erenumab (AIMOVIG): Amgen/Novartis
10.6.1. Product Description
10.6.2. Regulatory Milestones
10.6.3. Other Developmental Activities
10.6.4. Summary of Pivotal Trials
10.6.5. Analyst View
10.7. Diclofenac etalhyaluronate sodium (JOYCLU): SEIKAGAKU CORPORATION
10.7.1. Product Description
10.7.2. Regulatory Milestones
10.7.3. Other Developmental Activities
10.7.4. Summary of Pivotal Trials
10.7.5. Analyst View
10.8. Capsaicin (QUTENZA): Grunenthal/ Averitas Pharma
10.8.1. Product Description
10.8.2. Regulatory Milestones
10.8.3. Other Developmental Activities
10.8.4. Summary of Pivotal Trials
10.8.5. Clinical Development
10.8.5.1. Clinical Trials Information
10.8.6. Analyst View
10.9. Fremanezumab-vfrm (AJOVY): Teva Pharmaceuticals
10.9.1. Product Description
10.9.2. Regulatory Milestones
10.9.3. Other Developmental Activities
10.9.4. Summary of Pivotal Trials
10.9.5. Analyst views
10.10. Mirogabalin besilate (TARLIGE): Daiichi Sankyo
10.10.1. Product Description
10.10.2. Regulatory Milestones
10.10.3. Other Developmental Activities
10.10.4. Summary of Pivotal Trials
10.10.5. Analyst views
10.11. OnabotulinumtoxinA (BOTOX): AbbVie
10.11.1. Product Description
10.11.2. Regulatory Milestones
10.11.3. Other Developmental Activities
10.11.4. Summary of Pivotal Trials
10.11.5. Analyst views
10.12. Cyclobenzaprine hydrochloride (TONMYA): Tonix Pharmaceuticals
10.12.1. Product Description
10.12.2. Regulatory Milestones
10.12.3. Other Developmental Activities
10.12.4. Summary of Pivotal Trials
10.12.5. Analyst views
10.13. VER-01 (EXILBY): VERTANICAL
10.13.1. Product Description
10.13.2. Regulatory Milestones
10.13.3. Other Developmental Activities
10.13.4. Summary of Pivotal Trials
10.13.5. Clinical Development
10.13.5.1. Clinical trials information
10.13.6. Analyst View
10.14. Buprenorphine Buccal Film (BELBUCA): Collegium Pharmaceutical
10.14.1. Product Description
10.14.2. Regulatory Milestones
10.14.3. Other Developmental Activities
10.14.4. Summary of Pivotal Trial
10.14.5. Analyst View
10.15. Oxycodone ER abuse-deterrent (XTAMPZA ER): Collegium Pharmaceutical
10.15.1. Product Description
10.15.2. Regulatory Milestones
10.15.3. Other Developmental Activities
10.15.4. Summary of Pivotal Trials
10.15.5. Analyst View
To be continued in the report.

11. Emerging Drugs
11.1. Emerging Drugs: Competitive Landscape
11.2. SL1002: Saol Therapeutics
11.2.1. Product Description
11.2.2. Other Developmental Activities
11.2.3. Clinical Development
11.2.3.1. Clinical Trial Information
11.2.4. Analyst Views
11.3. Zenagamtide: Novo Nordisk
11.3.1. Product Description
11.3.2. Other Developmental activities
11.3.3. Clinical Development
11.3.3.1. Clinical Trial Information
11.3.4. Analyst view
11.4. AbobotulinumtoxinA (DYSPORT): Ipsen
11.4.1. Product Description
11.4.2. Other Developmental Activities
11.4.3. Clinical Development Activity
11.4.4. Safety and Efficacy
11.4.5. Analyst Views
11.5. AncobotulinumtoxinA (XEOMIN): Merz Therapeutics
11.5.1. Product Description
11.5.2. Other Developmental Activities
11.5.3. Clinical Development Activity
11.5.4. Analyst Views
11.6. Retatrutide (LY3437943): Eli Lilly and Company
11.6.1. Product Description
11.6.2. Other Developmental Activities
11.6.3. Clinical Development
11.6.3.1. Clinical Trial Information
11.6.4. Analyst View
11.7. Suzetrigine (JOURNAVX): Vertex Pharmaceuticals
11.7.1. Product Description
11.7.2. Other Developmental Activities
11.7.3. Clinical Development
11.7.3.1. Clinical Trial Information
11.7.4. Safety and Efficacy
11.7.5. Analyst Views
11.8. Esreboxetine (AXS-14): Axsome Therapeutics
11.8.1. Product Description
11.8.2. Other Developmental activities
11.8.3. Clinical Development
11.8.3.1. Clinical Trial Information
11.8.4. Safety and Efficacy
11.8.5. Analyst view
11.9. Rimegepant (NURTEC): Pfizer
11.9.1. Product Description
11.9.2. Other Developmental Activities
11.9.3. Clinical Development
11.9.3.1. Clinical Trial Information
11.9.4. Analyst Views
11.10. AMZ001: Amzell
11.10.1. Product Description
11.10.2. Other Developmental Activities
11.10.3. Clinical Development
11.10.3.1. Clinical Trial Information
11.10.4. Safety and Efficacy
11.10.5. Analyst Views
11.11. Lorecivivint (SM04690): Biosplice Therapeutics
11.11.1. Product Description
11.11.2. Other Developmental Activities
11.11.3. Clinical Development
11.11.3.1. Clinical Trial Information
11.11.4. Safety and Efficacy
11.11.5. Analyst Views
11.12. TLC599: Taiwan Liposome Company
11.12.1. Product Description
11.12.2. Other Developmental activities
11.12.3. Clinical Development
11.12.3.1. Clinical Trial Information
11.12.4. Safety and Efficacy
11.12.5. Analyst view
11.13. Rexlemestrocel-L (MPC-06-ID): Mesoblast and Grunenthal
11.13.1. Product Description
11.13.2. Other Developmental activities
11.13.3. Clinical Development
11.13.3.1. Clinical Trial Information
11.13.4. Safety and efficacy
11.13.5. Analyst view
11.14. Vicatertide (SB-01): Spine Biopharma
11.14.1. Product Description
11.14.2. Other Developmental Activities
11.14.3. Clinical Development
11.14.3.1. Clinical Trial Information
11.14.4. Safety and Efficacy
11.14.5. Analyst Views
11.15. Pentosan Polysulfate Sodium (ZILOSUL): Paradigm Biopharmaceuticals
11.15.1. Product Description
11.15.2. Other Developmental Activities
11.15.3. Clinical Development
11.15.3.1. Clinical Trial Information
11.15.4. Safety and Efficacy
11.15.5. Analyst view
11.16. Pilavapadin (LX9211): Lexicon Pharmaceuticals
11.16.1. Product Description
11.16.2. Other Developmental activities
11.16.3. Clinical Development
11.16.3.1. Clinical Trial Information
11.16.4. Safety and efficacy
11.16.5. Analyst view
11.17. Eloralintide (LY3841136): Eli Lily
11.17.1. Product Description
11.17.2. Other Developmental Activities
11.17.3. Clinical Development
11.17.3.1. Clinical Trial Information
11.17.4. Analyst View
11.18. Orforglipron (FOUNDAYO): Eli Lily
11.18.1. Product Description
11.18.2. Other Developmental Activities
11.18.3. Clinical Development
11.18.3.1. Clinical Trial Information
11.18.4. Analyst View
11.19. MOTYS (PTP-001): Doron Therapeutics
11.19.1. Product Description
11.19.2. Other Developmental Activities
11.19.3. Clinical Development
11.19.3.1. Clinical Trial Information
11.19.4. Safety and efficacy
11.19.5. Analyst's View
11.20. SEMDEXA (SP-102): Semnur Pharmaceuticals (Scilex Holding)
11.20.1. Product Description
11.20.2. Other Developmental Activities
11.20.3. Clinical Development
11.20.3.1. Clinical Trial Information
11.20.4. Safety and Efficacy
11.20.5. Analyst View
11.21. Rebonuputemcel (IDCT): DiscGenics
11.21.1. Product Description
11.21.2. Other Developmental Activities
11.21.3. Clinical Development
11.21.3.1. Clinical Trial Information
11.21.4. Safety and Efficacy
11.21.5. Analyst Views
To be continued in the report.

12. Chronic Pain: The 7MM Analysis
12.1. Key Findings
12.2. Market Outlook
12.3. Attribute Analysis
12.4. Key Market Forecast Assumptions
12.4.1. Cost Assumptions and Rebates
12.4.2. Pricing Trends
12.4.3. Analogue Assessment
12.4.4. Launch Year and Therapy Uptake
12.5. Market Size of Chronic Pain in the 7MM
12.6. Market Size of Chronic Pain by Therapies in the 7MM
12.7. The United States Market Size
12.7.1. Total Market Size of Chronic Pain in the US
12.7.2. Market Size of Chronic Pain by Therapies in the US
12.8. EU4 and the UK Market Size
12.8.1. Total Market Size of Chronic Pain in EU4 and the UK
12.8.2. Market Size of Chronic Pain by Therapies in EU4 and the UK
12.9. Japan Market Size
12.9.1. Total Market Size of Chronic Pain in Japan
12.9.2. Market Size of Chronic Pain by Therapies in Japan

13. Unmet Needs

14. SWOT Analysis

15. KOL Views

16. Market Access and Reimbursement
16.1. The United States
16.1.1. CMS
16.2. In EU4 and the UK
16.2.1. Germany
16.2.2. France
16.2.3. Italy
16.2.4. Spain
16.2.5. The United Kingdom
16.3. Japan
16.3.1. MHLW
16.4. Market Access and Reimbursement of Chronic Pain Therapies

17. Appendix
17.1. Bibliography
17.2. Report Methodology

18. Analyst's Capabilities

19. Disclaimer

20. About the Publisher

List of Tables
Table 1: Summary of Chronic Pain Epidemiology and Market (2025-2036)
Table 2: Examination & Testing for Diagnosing Chronic Pain (Japan Clinical Practice Guidelines)
Table 3: Pain-related Questionnaires & Scales
Table 4: Guidelines for Chronic Neuropathic Pain
Table 5: Total Diagnosed Prevalent Cases of Chronic Pain in the 7MM, in Thousands (2022-2036)
Table 6: Total Prevalent Cases of Chronic Pain in the US, in Thousands (2022-2036)
Table 7: Total Diagnosed Prevalent Cases of Chronic Pain in the US, in Thousands (2022-2036)
Table 8: Severity-specific Diagnosed Prevalent Cases of Chronic Pain in the US, in Thousands (2022-2036)
Table 9: Gender-specific Diagnosed Prevalent Cases of Chronic Pain in the US, in Thousands (2022-2036)
Table 10: Age -specific Diagnosed Prevalent Cases of Chronic Pain in the US, in Thousands (2022-2036)
Table 11: Cause-specific Diagnosed Prevalent Cases of Chronic Pain in the US, in Thousands (2022-2036)
Table 12: Total Treated Cases of Chronic Pain in the US, in Thousands (2022-2036)
Table 13: Total Prevalent Cases of Chronic Pain in EU4 and the UK, in Thousands (2022-2036)
Table 14: Total Diagnosed Prevalent Cases of Chronic Pain in EU4 and the UK, in Thousands (2022-2036)
Table 15: Severity-specific Diagnosed Prevalent Cases of Chronic Pain in EU4 and the UK, in thousands (2022-2036)
Table 16: Gender-specific Diagnosed Prevalent Cases of Chronic Pain in EU4 and the UK, in Thousands (2022-2036)
Table 17: Age-specific Diagnosed Prevalent Cases of Chronic Pain in EU4 and the UK, in Thousands (2022-2036)
Table 18: Cause-specific Diagnosed Prevalent Cases of Chronic Pain in EU4 and the UK, in Thousands (2022-2036)
Table 19: Total Treated Cases of Chronic Pain in EU4 and the UK, in Thousands (2022-2036)
Table 20: Total Prevalent Cases of Chronic Pain in Japan, in Thousands (2022-2036)
Table 21: Total Diagnosed Prevalent Cases of Chronic Pain in Japan, in Thousands (2022-2036)
Table 22: Severity -specific Diagnosed Prevalent Cases of Chronic Pain in Japan, in Thousands (2022-2036)
Table 23: Gender-specific Diagnosed Prevalent Cases of Chronic Pain in Japan, in Thousands (2022-2036)
Table 24: Age -specific Diagnosed Prevalent Cases of Chronic Pain in Japan, in Thousands (2022-2036)
Table 25: Cause-specific Diagnosed Prevalent Cases of Chronic Pain in Japan, in Thousands (2022-2036)
Table 26: Total Treated Cases of Chronic Pain in Japan, in Thousands (2022-2036)
Table 27: Marketed Drugs Competitive Landscape
Table 28: Atogepant (AQUIPTA,QULIPTA), Clinical Trial Description, 2026
Table 29: Triamcinolone acetonide extended-release injectable suspension (ZILRETTA), Clinical Trial Description, 2026
Table 30: Eptinezumab (VYEPTI) , Clinical Trial Description, 2026
Table 31: Capsaicin (QUTENZA), Clinical Trial Description, 2026
Table 32: VER-01 (EXILBY), Clinical Trial Description, 2026
Table 33: Comparison of Emerging Drugs Under Development for Chronic Pain
Table 34: SL1002, Clinical Trial Description, 2026
Table 35: Zenagamtide, Clinical Trial Description, 2026
Table 36: AbobotulinumtoxinA (DYSPORT), Clinical Trial Description, 2026
Table 37: AncobotulinumtoxinA (XEOMIN), Clinical Trial Description, 2026
Table 38: Retatrutide (LY3437943), Clinical Trial Description, 2026
Table 39: Suzetrigine, Clinical Trial Description, 2026
Table 40: Esreboxetine (AXS-14), Clinical Trial Description, 2026
Table 41: Rimegepant (NURTEC), Clinical Trial Description, 2026
Table 42: AMZ001 , Clinical Trial Description, 2026
Table 43: Lorecivivint (SM04690), Clinical Trial Description, 2026
Table 44: TLC599, Clinical Trial Description, 2026
Table 45: Rexlemestrocel-L (MPC-06-ID), Clinical Trial Description, 2026
Table 46: Vicatertide (SB-01), Clinical Trial Description, 2026
Table 47: ZILOSUL (iPPS/PPS), Clinical Trial Description, 2026
Table 48: Pilavapadin (LX9211), Clinical Trial Description, 2026
Table 49: Eloralintide (LY3841136), Clinical Trial Description, 2026
Table 50: Orforglipron (LY3502970), Clinical Trial Description, 2026
Table 51: MOTYS (PTP-001), Clinical Trial Description, 2026
Table 52: SEMDEXA (SP-102), Clinical Trial Description, 2026
Table 53: Rebonuputemcel (IDCT), Clinical Trial Description, 2026
Table 54: Safety and Efficacy
Table 55: Key Market Forecast Assumptions of Chronic Pain in the US
Table 56: Key Market Forecast Assumptions of Chronic Pain in EU4 and the UK
Table 57: Key Market Forecast Assumptions of Chronic Pain in Japan
Table 58: Total Market Size of Chronic Pain in the 7MM, in USD million (2022-2036)
Table 59: Market Size of Chronic Pain by Therapies in the 7MM, in USD million (2022-2036)
Table 60: Total Market Size of Chronic Pain in the US, in USD million (2022-2036)
Table 61: Market Size of Chronic Pain by Therapies in the US, in USD million (2022-2036)
Table 62: Total Market Size of Chronic Pain in EU4 and the UK, in USD million (2022-2036)
Table 63: Market Size of Chronic Pain by Therapies in EU4 and the UK, in USD million (2022-2036)
Table 64: Total Market Size of Chronic Pain in Japan, in USD million (2022-2036)
Table 65: Market Size of Chronic Pain by Therapies in Japan, in USD million (2022-2036)
Table 66: IQWiG Assessment for Chronic Pain Therapies
Table 67: Haute Autorite de Sante (HAS) Decisions for Chronic PainTherapies
Table 68: AIFA Assessment for Chronic Pain Therapies
Table 69: AEMPS Assessment for Chronic Pain Therapies
Table 70: NHI Pricing for Chronic Pain

List of Figures
Figure 1: Types of Chronic Pain
Figure 2: Classification of Chronic Pain
Figure 3: Causes of Chronic Pain
Figure 4: Risk factors of Chronic Pain
Figure 5: Pathophysiology of Chronic Pain
Figure 6: Diagnostic Algorithm of Chronic Pain
Figure 7: Treatment of Chronic Pain
Figure 8: Treatment Algorithm of Chronic Pain
Figure 9: Total Diagnosed Prevalent Cases of Chronic Pain in the 7MM, in Thousands (2022-2036)
Figure 10: Total Prevalent Cases of Chronic Pain in the US, in Thousands (2022-2036)
Figure 11: Total Diagnosed Prevalent Cases of Chronic Pain in the US, in Thousands (2022-2036)
Figure 12: Severity-specific Diagnosed Prevalent Cases of Chronic Pain in the US, in Thousands (2022-2036)
Figure 13: Gender-specific Diagnosed Prevalent Cases of Chronic Pain in the US, in Thousands (2022-2036)
Figure 14: Age -specific Diagnosed Prevalent Cases of Chronic Pain in the US, in Thousands (2022-2036)
Figure 15: Cause-specific Diagnosed Prevalent Cases of Chronic Pain in the US, in Thousands (2022-2036)
Figure 16: Total Treated Cases of Chronic Pain in the US,in Thousands (2022-2036)
Figure 17: Total Prevalent Cases of Chronic Pain in EU4 and the UK, in Thousands (2022-2036)
Figure 18: Total Diagnosed Prevalent Cases of Chronic Pain in EU4 and the UK, in Thousands (2022-2036)
Figure 19: Severity -specific Diagnosed Prevalent Cases of Chronic Pain in EU4 and the UK, in Thousands (2022-2036)
Figure 20: Gender-specific Diagnosed Prevalent Cases of Chronic Pain in EU4 and the UK, in Thousands (2022-2036)
Figure 21: Age-specific Diagnosed Prevalent Cases of Chronic Pain in EU4 and the UK, in Thousands (2022-2036)
Figure 22: Cause-specific Diagnosed Prevalent Cases of Chronic Pain in EU4 and the UK, in Thousands (2022-2036)
Figure 23: Total Treated Cases of Chronic Pain in EU4 and the UK, in Thousands (2022-2036)
Figure 24: Total Prevalent Cases of Chronic Pain in Japan, in Thousands (2022-2036)
Figure 25: Total Diagnosed Prevalent Cases of Chronic Pain in Japan, in Thousands (2022-2036)
Figure 26: Severity -specific Diagnosed Prevalent Cases of Chronic Pain in Japan, in Thousands (2022-2036)
Figure 27: Gender-specific Diagnosed Prevalent Cases of Chronic Pain in Japan , in Thousands (2022-2036)
Figure 28: Age -specific Diagnosed Prevalent Cases of Chronic Pain in Japan , in Thousands (2022-2036)
Figure 29: Cause-specific Diagnosed Prevalent Cases of Chronic Pain in Japan, in Thousands (2022-2036)
Figure 30: Total Treated Cases of Chronic Pain in Japan, in Thousands (2022-2036)
Figure 31: Total Market Size of Chronic Pain in the 7MM, in USD million (2022-2036)
Figure 32: Market Size of Chronic Pain by Therapies in the 7MM, in USD million (2022-2036)
Figure 33: Total Market Size of Chronic Pain in the US, in USD million (2022-2036)
Figure 34: Market Size of Chronic Pain by Therapies in the US, in USD million (2022-2036)
Figure 35: Total Market Size of Chronic Pain in EU4 and the UK, in USD million (2022-2036)
Figure 36: Market Size of Chronic Pain by Therapies in EU4 and the UK, in USD million (2022-2036)
Figure 37: Total Market Size of Chronic Pain in Japan, in USD million (2022-2036)
Figure 38: Market Size of Chronic Pain by Therapies in Japan, in USD million (2022-2036)
Figure 39: HTA
Figure 40: Reimbursement Process in US
Figure 41: Reimbursement Process in Germany
Figure 42: Reimbursement Process in France
Figure 43: Reimbursement Process in Italy
Figure 44: Reimbursement Process in Spain
Figure 45: Reimbursement Process in the United Kingdom
Figure 46: Reimbursement Process in Japan

A selection of companies mentioned in this report includes, but is not limited to:

AbbVie
Pacira Pharmaceuticals
Eli Lilly and Company
Lundbeck

For more information about this report visit https://www.researchandmarkets.com/r/f9e708

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: 
CONTACT: ResearchAndMarkets.com 
         Laura Wood,Senior Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900

Chronic Pain Market Poised for Growth Through 2036 as Rising Prevalence and Innovative Therapies Drive New Opportunities